EF
GLUE icon

Empowered Funds’s Monte Rosa Therapeutics GLUE Stock Holding History

Empowered Funds’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.02M Buy
305,398
+27,321
+10% +$522K 0.03% 636
2025
Q4 		$4.36M Buy
278,077
+190,627
+218% +$2.57M 0.07% 285
2025
Q3 		$648K Buy
+87,450
New +$463K 0.01% 1311

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Empowered Funds's GLUE Position: Q1 2026 in Review

Empowered Funds increased its Monte Rosa Therapeutics (GLUE) stake by 9.8% in Q1 2026, buying an estimated $522K and bringing the position to 305,398 shares worth $5.02M. The position accounts for 0.03% of the portfolio, ranked #636.

Empowered Funds first reported a position in GLUE in Q3 2025 and has held it in 3 quarters since. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Empowered Funds held 305,398 shares of Monte Rosa Therapeutics worth $5.02M as of Q1 2026.
  • Empowered Funds bought 27,321 Monte Rosa Therapeutics shares in Q1 2026, an estimated $522K.
  • Monte Rosa Therapeutics made up 0.03% of Empowered Funds's portfolio in Q1 2026, its #636 holding.
  • Empowered Funds first reported a position in Monte Rosa Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Empowered Funds's 13F filing for Q1 2026, filed 15 May 2026.